D-0309-2025 Class II Ongoing
FDA drug recall D-0309-2025 was initiated by Glenmark Pharmaceuticals Inc., USA on Mar 11, 2025 and is designated Class II. Reason for recall: CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit. The recall status is ongoing. Affected quantity: 8160 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 9, 2025
- Initiation Date
- Mar 11, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 8160 bottles
Product description
chlorproMAZINE Hydrochloride Tablets, USP 100 mg, Rx Only, 100 Tablets per bottle, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-864-01
Reason for recall
CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.
Distribution pattern
Nationwide in the USA and PR
Code information
Lot#s: 17232222 and 17232237, Exp 10/31/2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0309-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026